Skip to main content

Site notifications

TAFINLAR dabrafenib (as mesilate) 50 mg capsule bottle, Novartis Pharmaceuticals Australia Pty Ltd, CON-1427

Product name
TAFINLAR dabrafenib (as mesilate) 50 mg capsule bottle
Sponsor name
Novartis Pharmaceuticals Australia Pty Ltd
Consent start
Consent no.
CON-1427
Duration
The consent is effective from 4 November 2025 until 30 November 2026.
Standard
Paragraphs 8(1)(f) and 8(1)(g) of Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines
Non-compliance with standard
The products do not conform because they do not have the batch number and expiry date prefixes preceding the batch number or the expiry date respectively.
Import, Supply, &/or Export
import and supply
Therapeutic product type
Prescription medicines